Alzheimer’s Therapeutics Market By Drug Class (Cholinesterase inhibitors, N-Methyl-D-Aspartate (NMDA) receptor antagonist, Others), By Distribution Channel (Hospital Pharmacy, Drug Store and Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis a

Alzheimer’s Therapeutics Market By Drug Class (Cholinesterase inhibitors, N-Methyl-D-Aspartate (NMDA) receptor antagonist, Others), By Distribution Channel (Hospital Pharmacy, Drug Store and Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031

The global Alzheimer’s therapeutics market was valued $6,123 million in 2021 and expected to reach $13017.93 million by 2031, with a CAGR of 8.1% from 2022 to 2031.

Alzheimer’s disease is a brain disorder, which slowly destroys memory and thinking skills. It involves the part of the brain that controls thought, memory, and language. It is a progressive form of dementia which is a broader term for conditions which negatively affect memory, and behavior. Alzheimer’s disease causes loss of connection between nerve cells in the brain.  This damage initially takes place in the parts of the brain and then results in slow decline of memory which includes entorhinal cortex and later it affects in the areas such as cerebral cortex that is responsible for language, social behavior, and reasoning. Alzheimer’s disease also causes decline in the ability to make reasonable decisions and judgments in everyday situations. Increase in age is the greatest known risk factor of the Alzheimer’s disease. Also, researchers believe that genetics may play an important role in developing Alzheimer’s disease.  

The global Alzheimer’s therapeutics market is majorly driven by an alarming increase in the prevalence of Alzheimer’s disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis drive the growth of the market. For instance, in September 2021, according to World Health Organization, it was estimated that approximately 55 million people around the world suffering from Dementia. Dementia results from a variety of diseases and injuries that primarily affect the brain and Alzheimer’s disease is the most common form of dementia. In addition, as per Center for Disease Control and Prevention, in 2020, it was estimated that approximately 5.8 million American’s were living with Alzheimer’s disease and this is projected to reach nearly triple to 14 million by 2060. Thus, increasing number of cases of Alzheimer’s disease is resulting in growing demand for its treatment, which is subsequently driving the growth of the market.

For instance, in June 2021, Eli Lilly and Company has received an FDA approval for donaemab therapy. The donaemab therapy aims to treat a serious condition of Alzheimer’s disease. Thus, increasing number of product launch drives the substantial growth of the market.  Moreover, in April 2021, Amneal completed the acquisition of Kashiv Specialty Pharmaceuticals. This acquisition has aim to expand the Amneal’s business and it has gained pipeline of 505(b) 2 branded products and complex generics. Thus, rising number of acquisitions among key players drives the growth of the market.

Increase in investment by players in R&D and presence of robust pipeline candidates foster the market growth. In addition, rise in expenditure on the development of healthcare infrastructure, increase in public awareness about the disease prevention in developing regions, and surge in demand for personalized medicine are expected to create lucrative opportunities for the expansion of the Alzheimer’s therapeutics market.

According to Bright Focus Foundation Alzheimer’s Disease Facts & Figures,  in 2021, it was estimated that there were approximately 6.5 million people were suffering from Alzheimer’s disease in the U.S and is projected to reach to 12.7 million by 2050. In addition, as per same source, in 2021, it was estimated that nearly 500,000 new cases of Alzheimer’s disease were diagnosed in the U.S. Thus, increasing number of people suffer from Alzheimer’s disease propels the growth of the market.

Alzheimer’s disease is the most common in Western Europe and least common in Sub-Saharan Africa. African-Americans are about twice as likely to have Alzheimer’s disease. According to Alzheimer’s Drug Discovery Foundation Diagnostics Accelerator, in 2021, has launched four new research investments for the development of digital biomarkers for Alzheimer’s diagnosis. Thus, rising number of investments by private healthcare organizations for the management of Alzheimer’s disease drives the growth of the market. Additionally, the advancement in the ongoing research activities of pharmaceutical companies and their product offering, launching new products, and other business expansion initiatives such as merger and acquisition, collaborations and new investments into other companies are expected to drive the growth of the market.

However, the global Alzheimer’s therapeutics market is anticipated to be hampered by issues such as the high cost of therapeutics. Moreover, increase in awareness among the population for early diagnosis led to the enhancement of the Alzheimer’s therapeutics sector. This encourages many key players to enter emerging markets, thus offering a lucrative growth opportunity in the Alzheimer’s therapeutics market. Moreover, surge in the research and development activities for the development of novel drugs and therapies, increasing older population leads to rise number of Alzheimer’s disease cases drives the growth of the market.

The Alzheimer’s therapeutics market is studied across by drug class, distribution channel, and region. On the basis of drug class, it is categorized into Cholinesterase inhibitors, N-methyl D-Aspartate Receptor Antagonist, and others. By distribution channel it is divided into hospital pharmacy, drug stores & retail pharmacy, and online pharmacy. By region, the Alzheimer’s therapeutics market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Major players operating in the Alzheimer’s therapeutics market are Biogen Inc., Merck & Co. Inc., Novartis AG, Eisai Co. Ltd., H.Lundbeck A/S, Daiichi Sankyo Company Ltd., AbbVie Inc., Teva Pharmaceuticals Industries Ltd., Eli Lilly and Company, and Lupin.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the alzheimer’s therapeutics market analysis from 2021 to 2031 to identify the prevailing alzheimer’s therapeutics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the alzheimer’s therapeutics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global alzheimer’s therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

Cholinesterase inhibitors
N-Methyl-D-Aspartate (NMDA) receptor antagonist
Others

By Distribution Channel

Hospital Pharmacy
Drug Store and Retail Pharmacy
Online Pharmacy

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest Of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest Of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest Of LAMEA

Key Market Players

Biogen
Merck & Co. Inc.
Novartis AG
Eisai Co. Ltd.
H. Lundbeck A/S
DAIICHI SANKYO COMPANY, LIMITED
AbbVie Inc.
Teva Pharmaceuticals Industries Ltd.
Eli Lilly and Company
Lupin Ltd

Please Note: It will take 7-10 business days to complete the report upon order confirmation.